MedTrace Logo

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

NCT00469599 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2011-04-04

No results posted yet for this study

Summary

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Conditions

Interventions

DRUG

paricalcitol

3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate

DRUG

alfacalcidol

1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Ditte Hansen, MD · Zealand University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-09-30
Completion
2010-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469599 on ClinicalTrials.gov